Perspective Therapeutics (CATX) EBITDA Margin (2010 - 2023)

Perspective Therapeutics (CATX) posted EBITDA Margin of 238.19% for Q4 2023, up 153.38% sequentially from 446.22% in Q3 2023.

Perspective Therapeutics (CATX) EBITDA Margin (2010 - 2023) Analysis & Trends

Perspective Therapeutics has reported EBITDA Margin for 14 years, with the latest figure at 238.19% in Q4 2023.

Quarterly EBITDA Margin changed N/A year-over-year to 238.19% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4839.36% (changed N/A YoY) and the FY2023 annual result came in at 2855.02%, changed N/A from the prior year.
EBITDA Margin improved to 238.19% in Q4 2023 per CATX's latest filing, from 446.22% in the prior quarter.
Over five years, EBITDA Margin peaked at 238.19% in Q4 2023 and troughed at 650.27% in Q2 2023.
A 5-year average of 105.92% and a median of 52.17% in 2020 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2021 and 2023: EBITDA Margin jumped 10184 bps in 2021, then tumbled 58596 bps in 2023.
Over 5 years, EBITDA Margin stood at 40.93% in 2019, then climbed by 10 bps to 37.01% in 2020, then plunged by 57 bps to 58.06% in 2021, then tumbled by 86 bps to 107.82% in 2022, then soared by 321 bps to 238.19% in 2023.
According to Business Quant data, EBITDA Margin over the past three periods registered 238.19%, 446.22%, and 650.27% for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	13.44%
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn	25.18%
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn	19.10%
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn	29.48%
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	10.30%
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn	19.15%
10	Perspective Therapeutics	387.89 Mn	387.89 Mn	-	-

Download Data